Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension

In patients with treatment-resistant hypertension and blood pressure of 130/80 mm Hg or higher, the aldosterone synthase inhibitor baxdrostat reduced blood pressure in a dose-related manner.

Saved in:

Bibliographic Details
Published in:	The New England journal of medicine Vol. 388; no. 5; pp. 395 - 405
Main Authors:	Freeman, Mason W., Halvorsen, Yuan-Di, Marshall, William, Pater, Mackenzie, Isaacsohn, Jon, Pearce, Catherine, Murphy, Brian, Alp, Nicholas, Srivastava, Ajay, Bhatt, Deepak L., Brown, Morris J.
Format:	Journal Article
Language:	English
Published:	United States Massachusetts Medical Society 02-02-2023
Subjects:	Aldosterone Aldosterone - blood Aldosterone - metabolism Aldosterone synthase Antihypertensive Agents - adverse effects Antihypertensive Agents - therapeutic use Antihypertensives Blood pressure Blood Pressure - drug effects Cardiology Clinical Medicine Clinical Medicine General Cortisol Cytochrome P-450 CYP11B2 - antagonists & inhibitors Diabetes Diuretics Double-Blind Method Endocrinology Endocrinology General Enrollments Humans Hypertension Hypertension - drug therapy Hypertension - etiology Lipids Nephrology Nephrology General Patients Placebos Potassium Prevention Regression analysis United States > US
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	In patients with treatment-resistant hypertension and blood pressure of 130/80 mm Hg or higher, the aldosterone synthase inhibitor baxdrostat reduced blood pressure in a dose-related manner.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Undefined-3
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa2213169